A QUICK OVERVIEW OF NANOMEDICINE APPLICATIONS IN BREAST CANCER DETECTION, IMAGING, AND THERAPY

Full Article - PDF

Published: 2022-02-27

Page: 109-121


RAMU SAMINENI *

Faculty of Pharmacy, Department of Pharmaceutical Sciences, Vignan’s Foundation for Science, Technology and Research, Vadlamudi, Guntur-522213, Andhra Pradesh, India.

JITHENDRA CHIMAKURTHY

Faculty of Pharmacy, Department of Pharmaceutical Sciences, Vignan’s Foundation for Science, Technology and Research, Vadlamudi, Guntur-522213, Andhra Pradesh, India.

K. UDAYARATNA

Department of Pharmaceutical Sciences, Vignan’s Foundation for Sciences, Technology and Research, Vadlamudi, Guntur-522213, Andhra Pradesh, India.

K. DEVATULASI

Department of Pharmaceutical Sciences, Vignan’s Foundation for Sciences, Technology and Research, Vadlamudi, Guntur-522213, Andhra Pradesh, India.

B. VARSHITHA REDDY

Department of Pharmaceutical Sciences, Vignan’s Foundation for Sciences, Technology and Research, Vadlamudi, Guntur-522213, Andhra Pradesh, India.

G. KEERTHI SRI

Department of Pharmaceutical Sciences, Vignan’s Foundation for Sciences, Technology and Research, Vadlamudi, Guntur-522213, Andhra Pradesh, India.

AGER DENG GOC

Department of Pharmaceutical Sciences, Vignan’s Foundation for Sciences, Technology and Research, Vadlamudi, Guntur-522213, Andhra Pradesh, India.

*Author to whom correspondence should be addressed.


Abstract

Breast cancer continues to be a global public health dilemma and is currently the most prevalent tumor in the world. Breast cancer awareness, public attention, and progress in the breast imaging have had a positive impact on breast cancer recognition and screening. Breast cancer is a fatal disease in females and the leading cause of death in females. Over the past two decades, studies related to breast cancer have guided amazing advances in our understanding of breast cancer, leading to more competent treatments. Among all the malignant diseases, breast cancer is one of the most common causes of mortality among postmenopausal women, accounting for 23% of all cancer fatalities. This is a global problem today, but it is still diagnosed in its advanced stages due to women's neglect concerning about the self-inspection and clinical examination of the breast. This review presents different types of breast cancer, symptoms, risk factors, epidemiology of breast cancer, stages of breast cancer, diagnostic investigations, and treatment. Chemotherapy, targeted therapies, surgery, radiation therapy, hormone replacement therapy, complementary therapies, gene therapy, and stem-cell therapy are some of the treatments for breast cancer. In this review, various applications of nano-carriers were discussed such as nanopolymers, Nanoshells, nanocrystals, quantum dots, and dendrimers were examined, as well as their potential in early cancer diagnosis and therapy.

Keywords: Nanomedicine, Cancer detection, Cancer Treatment, Chemotherapy, Tumors, Nanoshells


How to Cite

SAMINENI, R., CHIMAKURTHY, J., UDAYARATNA, K., DEVATULASI, K., REDDY, B. V., SRI, G. K., & GOC, A. D. (2022). A QUICK OVERVIEW OF NANOMEDICINE APPLICATIONS IN BREAST CANCER DETECTION, IMAGING, AND THERAPY. Asian Journal of Advances in Medical Science, 4(1), 109–121. Retrieved from https://mbimph.com/index.php/AJOAIMS/article/view/2886

Downloads

Download data is not yet available.

References

Cancer-Its various types along with causes, symptoms, treatments and stages, in: cancer info guide; 2009.

Available:http://www.cancer-info-guide.com/ (18 Aug. 2021).

Mieszkowski MR. Cancer – A biophysicist’s point of view. In: Digital Recordings; 2006. Available:http://www.digitalrecordings.com/publ/cancer.html (18 Aug 2021).

Immune system. In: Kids Health; 2010. Available:http://kidshealth.org/parent/gener al/body basics/immune.html# (16 Aug. 2021).

Helmberg A. Carcinogenesis; 2010.

Available:http://helmberg.at/carcinogenesis. htm (18 Aug. 2021).

Diet and Physical Activity: What’s the Cancer Connection? In: Prevention & Early Detection; 2009.

Margot. New SEER Report Documents High Risk of Second Cancers in Cancer Survivors. Oncology Times. 2007;29(5):8.

Ershler WB. The Influence of Advanced Age on Cancer Occurrence and Growth. In: Balducci L, Extermann M, editors. Biological Basis of Geriatric Oncology. Springer US; 2005;124:75-87.

Breast cancer. Merck; 2008.

Available: http://www.merck.com/mmhe/sec 22/ch251/ch251f.html (8 Sept. 2021).

Types of breast cancer. Rethink breast cancer; 2003.

Available:http://www.rethinkbreastcancer.co m/types_of_breast_cancer.html (8 Sept. 2021).

Types of breast cancer. Abviva; 2009. Available:http://abviva.com/1.html (8 Sept. 2021).

Ductal breast cancer. Cancer studies; 2021. Available:http://cancerstudies.com/ductal-breast-cancer (8 Sept. 2021).

Fayed L. Types of breast cancer. About.com: Cancer; 2009.

Available:http://cancer.about.com/od/breast cancer/a/cancertypes.htm (8 Sept. 2021).

Stephan P. Mucinous (Colloid) Carcinoma of the breast. About.com: Cancer; 2008. Available:http://breastcancer.about.com/od/ types/p/mucinous_ca.htm (8 Sept. 2021).

Stephan P. What you need to know about breast cancer symptoms. About.com: Breast cancer; 2007).

Available:http://breastcancer.about.com/od/ what is breast cancer/a/b/c symptoms .htm (8 Sept. 2021).

Stages of breast cancer, Breast cancer.org; 2010.

Available: http://www.breastcancer.org / symptoms/diagnosis/staging.jsp (20 August 2021).

Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, Vierkant RA, et al. Benign breast disease and the risk of breast cancer. N Engl J Med. 2005; 353:229-237.

Eberl MM, Sunga AY, Farrell CD, Mahoney MC. Patients with a Family History of Cancer: Identification and Management. JABFM. 2005;18: 211-217.

Breast cancer. Emedicine health; 2010. Available:http://www.emedicinehealth.com/b reast cancer/page2_em.htm (20 Aug 2021).

Fletcher SW. Patient information: Risk factor for breast cancer. Up-To Date; 2008. Available:http://www.utdol.com/patients/con tent/topic.do?topicKey=_rZvVFHbE jbw (20 Aug 2021).

Tiernan AM. Behavioral risk factor in breast cancer: Can risk be modified? The Oncologist. 2003;8:326-334.

Definite breast cancer risks. CancerHelp UK; 2008.

Available:http://www.cancerhelp.org.uk/type /breastcancer/about/risks/definite-breast cancer-risks (20 Aug 2021).

Stephan P. What you need to know about breast cancer symptoms. About.com: Breast cancer; 2007).

Available: http://breastcancer.about.com/od/ what is breast cancer/a/bc_symptoms .htm (20 Mar 2021).

Smith R. A. Cokkinides V., Brawley O. W. Cancer screening in the United States, 2008. CA Cancer J Clin. 2008;58:161-179.

Lippman ME, Breast cancer, Fauci AS. editors. Harrison’s Principles of Internal Medicine. 17th ed. Library of Congress Cataloging in Publication Data; 2008.

Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2008. CA Cancer J Clin. 2008;58:161-179.

Lippman ME, Breast cancer, Fauci AS. editors. Harrison’s Principles of Internal Medicine. 17th ed. Library of Congress Cataloging in Publication Data; 2008.

Breast cancer treatment, the breast cancerInfo.com. Available:http://thebreastcancerinfo.com/bre ast_cancer_treatment.htm (21 Mar 2010).

Surgical oncology. UT health science center; 2009.

Available:http://www.surgery.uthscsa.edu/s urgicaloncology/breast.asp (21 Aug 2021).

Rath GK. Radiation Therapy in the Management of Cancer. 50 Years of Cancer Control in India; 2021.

Available:http://mohfw.nic.in/pg96to104.pdf (21 Aug 2021).

Detailed guide: Breast cancer radiation therapy. American cancer society; 2009.

Available:http://www.cancer.org/docroot/CRI /content/CRI_2_4_4X_Radiation_Therapy_5.asp?sitearea (21 Aug 2021).

Breast health chemotherapy for breast cancer treatment; University Virginia Health System; 2006.

Available:http://www.healthsystem.virginia.edu/uvahealth/adult_breast/chemo. cfm (21 Aug 2021).

Cancer. Wellness.com; 2006-2010.

Available: http://www.wellness.com/reference /conditions/cancer/prevention-andtreatment (21 Aug 2021).

Wells BG. Breast Cancer, Pharmacotherapy hand book. 5th ed. New Delhi, Tata McGraw hill publishing company limited; 2004.

Jin-Hui W, Xin-Yuan L. Targeting Strategies in Cancer Gene Therapy. ACTA Biochimica and biophysica sinica. 2003;35:311-316.

Disis ML, Park KH. Immunomodulation of breast cancer via tumor antigen specific Th1. Cancer res treat. 2009;41:117-121.

Di Wu Mengjie Si Hui-Yi Xue Ho-Lun Wong. Nanomedicine applications in the treatment of breast cancer: current state of the art. International Journal of Nanomedicine. 2017;12:5879–5892

Tanaka T, Decuzzi P, Cristofanilli M, Sakamoto JM, Tasciotti V, Robertson FM, Ferrari M. Nanotechnology for breast cancer therapy. Biomed Microdevices. 2009;11:49-63.

Yamaan Saadeh1, Tiffany Leung1, Arpita Vyas1, Lakshmi Shankar Chaturvedi1, Omathanu Perumal2, and Dinesh Vyas. Applications of Nanomedicine in Breast Cancer Detection, Imaging, and Therapy. J. Nanosci. Nanotechnol. 2014;14(1):913–923. DOI:10.1166/jnn.2014.8755

Park JW. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res. 2002;4:3.

Patil Y, Sadhukha T, Ma L, Panyam J. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J. Control Release. 2009;136:1.

Yezhelyev MV, Gao X, Xing Y, Al-Hajj A, Nie S, et al. Emerging use of nanoparticles in diagnosis and treatment of breast cancer. Lancet Oncol. 2006;7:8.

Bharali DJ, Khalil, Gurbuz MM, Simone TM, Mousa SA. Nanoparticles and cancer therapy: A concise review with emphasis on dendrimers. Int. J. Nanomed. 2009;4.

Yang XQ, Chen C, Peng CW, Hou JX, Liu SP, et al. Quantum dot-based quantitative immunofluorescence detection and spectrum analysis of epidermal growth factor receptor in breast cancer tissue arrays. Int. J. Nanomed. 2011;6.

Medintz IL, Mattoussi H, Clapp AR. Potential clinical applications of quantum dots. Int. J. Nanomed. 2008;3:2.

Rejinold NS, Chennazhi K, Nair SV, Jayakumar R. Thermo-responsive chitosan-graft-poly(N-isopropyl acrylamide) co-polymeric nanoparticles for 5-fluorouracil delivery to breast cancer cells in vitro. J. Nanopharm. Drug Delivery. 2013;1:1.

Acharya S, Dilnawaz F, Sahoo SK. Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy. Biomaterials. 2009;30:29.

Day ES, Bickford LR, Slater JH, Riggall NS, Drezek RA, West JL. Antibody-conjugated gold-gold sulfide nanoparticles as multifunctional agents for imaging and therapy of breast cancer. Int J Nanomed. 2010;5:445–454.

Narahari Narayan Palei, S. Ramu, V. Vijaya, K. Thamizhvanan. Green synthesis of silver nanoparticles using leaf extract of Lantana camara and its antimicrobial activity. International Journal of Green Pharmacy. 2020; 14(1): 1-7

Ding H, Gangalum PR, Galstyan A, et al. HER2-positive breast cancer targeting and treatment by a peptide-conjugated mini nanodrug. Nanomedicine. 2017;13(2):631–639.

Tang Y, Soroush F, Tong Z, Kiani MF, Wang B. Targeted multidrug delivery system to overcome chemoresistance in breast cancer. Int J Nanomed. 2017;12:671–681.

Jiang L, He B, Pan D, Luo K, Yi Q, Gu Z. Anti-cancer efficacy of paclitaxel loaded in pH triggered liposomes. J Biomed Nanotechnol. 2016; 12(1):79–90.

Cheng B, Lu B, Liu X, et al. A pH-responsive glycolipid-like nanocarrier for optimising the time-dependent distribution of free chemical drugs in focal cells. Int J Pharm. 2017;522(1):210–221.

Xu CF, Zhang HB, Sun CY, et al. Tumor acidity-sensitive linkagebridged block copolymer for therapeutic siRNA delivery. Biomaterials. 2016;88:48–59.

Niu M, Valdes S, Naguib YW, Hursting SD, Cui Z. Tumor-associated macrophage-mediated targeted therapy of triple-negative breast cancer. Mol Pharm. 2016;13(6):1833–1842.

Zhang X, Tian W, Cai X, et al. Hydrazinocurcumin encapsuled nanoparticles “re-educate” tumor-associated macrophages and exhibit anti-tumor effects on breast cancer following STAT3 suppression. PLoS One. 2013;8(6):e6589

Cullis JE, Siolas D, Avanzi A, Barui S, Maitra A, Bar-Sagi D. Macropinocytosis of nab-paclitaxel drives macrophage activation in pancreatic cancer. Cancer Immunol Res. 2017;5(3):182–190.

Di Wu Mengjie Si Hui-Yi Xue Ho-Lun Wong. Nanomedicine applications in the treatment of breast cancer: current state of the art. International Journal of Nanomedicine 2017:12 5879–5892.

Paulmurugan R, Bhethanabotla R, Mishra K, et al. Folate receptor– targeted polymeric micellar nanocarriers for delivery of orlistat as a repurposed drug against triple-negative breast cancer. Mol Cancer Ther. 2016;15(2):221–231.

Sneider A, Jadia R, Piel B, VanDyke D, Tsiros C, Rai P. Engineering remotely triggered liposomes to target triple negative breast cancer. Oncomedicine. 2017;2:1–13.

Mamot C, Ritschard R, Wicki A, et al. Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells. J Drug Target. 2012;20(5): 422–432.

Shu D, Li H, Shu Y, et al. Systemic delivery of anti-miRNA for suppression of triple negative breast cancer utilizing RNA nanotechnology. ACS Nano. 2015;9(10):9731–9740.

Swaminathan SK, Roger E, Toti U, Niu L, Ohlfest JR, Panyam J. CD133- targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer. J Control Release. 2013;171(3):280–287

Muntimadugu E, Kumar R, Saladi S, Rafeeqi TA, Khan W. CD44 targeted chemotherapy for co-eradication of breast cancer stem cells and cancer cells using polymeric nanoparticles of salinomycin and paclitaxel. Colloids Surf B Biointerfaces. 2016;143:532–546

Rao W, Wang H, Han J, et al. Chitosan-decorated doxorubicinencapsulated nanoparticle targets and eliminates tumor reinitiating cancer stem-like cells. ACS Nano. 2015;9(6):5725–5740.

Banerjee J, Hanson AJ, Gadam B, et al. Release of liposomal contents by cell-secreted matrix metalloproteinase-9. Bioconjug Chem. 2009;20(7):1332–1339.

Qin C, He B, Dai W, et al. Inhibition of metastatic tumor growth and metastasis via targeting metastatic breast cancer by chlorotoxinmodified liposomes. Mol Pharm. 2014;11(10):3233–3241.

Ernsting MJ, Murakami M, Undzys E, Aman A, Press B, Li SD. A docetaxel-carboxymethylcellulose nanoparticle outperforms the approved taxane nanoformulation, Abraxane, in mouse tumor models with significant control of metastases. J Control Release. 2012;162(3): 575–581.